Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A9 | P48067 | 7/20 | 0.38 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.35 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.35 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.35 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4754247 | 0.86 | SLC6A9 (0.39) | SLC6A9SMYD3MEN1ALDH1A1MAPK1 | |
| SCHEMBL4830910 | 0.78 | CYP2C9 (0.41) | ALDH1A1 | |
| SCHEMBL11920254 | 0.75 | CYP2C9 (0.39) | MEN1ALDH1A1MAPK1KMT2A | |
| SCHEMBL11920255 | 0.74 | CYP2C9 (0.38) | SMYD3MEN1ALDH1A1MAPK1KMT2A | |
| SCHEMBL1364966 | 0.69 | CYP2C9 (0.46) | SMYD3 | |
| SCHEMBL1364968 | 0.69 | CYP2C9 (0.46) | SMYD3 | |
| SCHEMBL1365312 | 0.68 | CYP2C9 (0.43) | SMYD3MEN1ALDH1A1MAPK1KMT2A | |
| SCHEMBL1365315 | 0.68 | CYP2C9 (0.43) | SMYD3MEN1ALDH1A1MAPK1KMT2A | |
| SCHEMBL2830549 | 0.68 | CYP2C9 (0.41) | SMYD3MEN1ALDH1A1MAPK1KMT2A | |
| SCHEMBL2149418 | 0.68 | CYP2C9 (0.41) | SMYD3MEN1ALDH1A1MAPK1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8173639-B2 | Isoquinolinone derivatives as NK3 antagonists | H. LUNDBECK A/S (DK) | 2012-05-08 | — | — | US | disclosed |
| US-20090143402-A1 | ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS | H. LUNDBECK A/S (DK) | 2009-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090143402-A1 | ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS | KCNQ3, KCNK3, GRIK3 | SLC6A9 742/4885SMYD3 2484/4885MEN1 3960/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.